Fresh Off Its Nasdaq Debut, a Regenerative-Medicine Upstart Is Stacking Its Board With Big-Pharma Firepower
Issued on behalf of Conexeu Sciences Inc. A clutch of new directors with Fortune 500 finance, M&A, and aesthetics pedigrees signals that the newly public tissue-regeneration company is building for commercialization — in one of medicine's most consequential frontiers. RENO, Nev., June 16,...
Issued on behalf of Conexeu Sciences Inc. A clutch of new directors with Fortune 500 finance, M&A, and aesthetics pedigrees signals that the newly public tissue-regeneration company is building for commercialization — in one of medicine's most consequential frontiers. RENO, Nev., June 16,...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.